Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, open-label, single-arm, phase II clinical trial to evaluate the efficacy and safety of INCMGA00012 in Advanced Penile Squamous Cell Carcinoma


Clinical Trial Description

Men age ≥ 18 years with locally advanced unresectable or metastatic PSqCC stage 4 (i.e. T4 or N3 or M1) that are presenting with radiologic progression of disease (PD) following or not standard treatment with chemotherapy. After signing the ICF and confirmed eligibility, patients will receive INCMGA00012 500 mg by intravenous infusion on Day1 of each cycle, once every four weeks for up to 2 years. Patients will receive treatment until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason. Patients discontinuing the study treatment period will enter a post-treatment follow-up period during which survival and new anti-cancer therapy information will be collected every 3 months (± 14 days) from the last dose of investigational product until the end of study (EoS). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04231981
Study type Interventional
Source MedSIR
Contact
Status Active, not recruiting
Phase Phase 2
Start date April 28, 2020
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Completed NCT03686332 - PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study Phase 2
Completed NCT05518201 - Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old Phase 1
Recruiting NCT04708470 - A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Phase 1/Phase 2
Active, not recruiting NCT04357873 - Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations Phase 2
Terminated NCT00058448 - S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED) Phase 2
Recruiting NCT02817958 - Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis Phase 2
Completed NCT02280811 - T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Phase 2
Recruiting NCT02994758 - Development of Diagnostics and Treatment of Urological Cancers N/A
Completed NCT00019110 - Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Phase 1
Completed NCT04574427 - INtra-operative Evaluation of a Novel FLUorescENt C-mEt Tracer in Penile and Tongue
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Recruiting NCT05946993 - Linking In With Advice and Supports for Men Impacted by Metastatic Cancer N/A
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT05686226 - E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers Phase 2
Completed NCT05376202 - Image Guided Penile Cancer Surgery Phase 1
Recruiting NCT05264337 - Lymphedema After Urologic Surgery
Recruiting NCT03774901 - Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma Phase 2
Completed NCT01209325 - Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males Phase 2
Recruiting NCT05592639 - VideoEndoscopic Radical Inguinal Lymphadenectomy for Penile Cancer N/A
Completed NCT00066391 - Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer Phase 2